Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses

Brzezinski J, Choufani S, Romao R, Shuman C, Chen H, Cunanan J, Bagli D, Grant R, Lorenzo A, Weksberg R. Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses. Br J Cancer. 2021 Jan;124(2):437-446. doi: 10.1038/s41416-020-01102-1. Epub 2020 Oct 5. PMID: 33012783; PMCID: PMC7853092.

Although cure rates for Wilms tumours (WT) are high, many patients receive therapy with attendant long-term complications. Our goal was to stratify WT using genome-wide analyses to identify candidate molecular features for patients who would benefit from a reduction in therapy. We generated DNA methylation and exome sequencing data on WT–kidney pairs (n = 57) and unpaired tumours (n = 27) collected either at our centre or by the Children’s Oncology Group. Samples were divided into a discovery set (n = 32) and validation set (n = 52).